Plain-English translation of NCT07202559 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
You may be scheduled for extracorporeal shock wave lithotripsy (ESWL), a procedure that uses shock waves to break up stones in your pancreas. This trial tests whether combining aggressive intravenous fluid treatment with indomethacin—a medication given by rectal suppository—prevents pancreatitis (pancreas inflammation) better than using indomethacin alone. The goal is to find the safest, most effective way to protect you from serious complications after this procedure.
Pancreatitis is a serious complication that can happen after shock wave treatment of pancreatic stones. Doctors already use indomethacin to help prevent it, but they want to know if adding aggressive fluid replacement improves protection and leads to better outcomes for patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to one of two groups. Both groups will receive a 100 mg indomethacin suppository 30 minutes before your shock wave procedure. One group will also receive aggressive intravenous fluids (lactated Ringer's solution) during and after the procedure, while the other group will receive limited fluids. Researchers will then monitor you to see if you develop pancreatitis and compare outcomes between the two groups.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
China